Breaking News Instant updates and real-time market news.

PBYI

Puma Biotechnology

$38.05

1.35 (3.68%)

16:21
03/01/17
03/01
16:21
03/01/17
16:21

Puma Biotechnology reports Q4 adjusted EPS ($1.22), consensus ($1.92)

Reports Q4 R&D expenses $56.4M vs $52.5M last year. "We made significant progress with the neratinib clinical program during the fourth quarter," said Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma. "We presented additional results of several ongoing studies at the 2016 San Antonio Breast Cancer Symposium, including our Phase II CONTROL trial of PB272 in the extended adjuvant treatment of HER2-positive early stage breast cancer; a biomarker analysis of the NSABP FB-7 Phase II trial for the neoadjuvant treatment of HER2-positive locally advanced breast cancer; and the Phase II SUMMIT trial of PB272 for ERBB2 mutant, HER2 non-amplified metastatic breast cancer. We also initiated a Managed Access Program for PB272 outside the United States, providing physicians and patients access to PB272 when there are limited or no other therapeutic options available."

  • 21

    Jul

PBYI Puma Biotechnology
$38.05

1.35 (3.68%)

11/14/16
JPMS
11/14/16
NO CHANGE
JPMS
Puma Biotechnology selloff today an overreaction, says JPMorgan
JPMorgan analyst Cory Kasimov views the selloff today in shares of Puma Biotechnology as an overreaction. The diarrhea rates included in abstract posted today are worse than the last update, but the rates are equivalent to a median number of around 1 episode per patient in the first cycle of treatment, Kasimov tells investors in an intraday research note. He continues to consider neratinib an approvable drug based on currently available data.
11/14/16
STFL
11/14/16
NO CHANGE
Target $88
STFL
Buy
Stifel calls Puma selloff overdone, but concerned by management comments
Stifel analyst Thomas Shrader views the intraday selloff in Puma Biotechnology shares as an overreaction, but he calls management's comments last week "an issue." At a conference last week, management said, "In December, we showed the interim results of this and as you can see the grade 3 diarrhea ranged from 13% to 18%. And also, all of the things that would be involved in tolerability, like stopping the drug, reducing the drug, or discontinuing were all brought down as well. Here, you can see the diarrhea over time in the control study." Shrader believes today's abstract was likely embargoed, but he still finds last week's comments "strange." Nonetheless, the analyst feels neratinib's Grade 3 diarrhea rate is manageable and he notes that Grade 4 diarrhea events were zero in all arms of the trial. Shrader has a Buy rating on Puma with an $88 price target.
01/03/17
SBSH
01/03/17
NO CHANGE
Target $88
SBSH
Buy
Citi finds 'bullish' Youtube videos for Puma cancer drug
Two new "Key Opinion Leader" videos expressing continued optimism on Puma Biotechnology's breast cancer drug neratinib posted on Youtube within the last several weeks, Citi analyst Yigal Nochomovitz tells investors in a research note. Similar to two videos posted in August, the new videos have received very little online attention with 25-30 views, the analyst contends. Nochomovitz believes Key Opinion Leader interest in neratinib continues to accelerate. The analyst notes a doctor in one of the videos said the chances of getting "significant diarrhea go way, way down" after a month. He keeps a Buy rating on Puma shares with an $88 price target. The stock closed Friday up 15c to $30.70.
02/01/17
SBSH
02/01/17
NO CHANGE
Target $88
SBSH
Buy
Citi sees Puma doubling if Roche study is negative
Citi analyst Yigal Nochomovitz believes shares of Puma Biotechnology (PBYI) could rally 100% or more if Roche (RHHBY) reports a negative Phase III Aphinity study readout of Perjeta in the adjuvant treatment of HER2-positive early breast cancer. The analyst, which notes Roche slides today point to a data readout in late February or early March, sees maximum downside for Puma shares of 30% should Aphinity succeed. A selloff would be a "very good opportunity to buy the dip" as despite the controversy around neratinib's benefit/risk profile, neratinib should be approved by the FDA for extended adjuvant, Nochomovitz tells investors in a research note. The FDA action date for neratinib is in July. The analyst adds that recent stock sales by Puma management were in the context of tax obligations required for vesting of restricted stock units. Management's net ownership in the company has actually increased with the vesting of a tranche of restricted stock, Nochomovitz writes. He has a Buy rating on Puma with an $88 price target. The stock is unchanged at $32.40 in morning trading.

TODAY'S FREE FLY STORIES

BHP

BHP Billiton

$43.08

0.74 (1.75%)

, XOM

Exxon Mobil

$83.03

0.13 (0.16%)

18:29
12/17/17
12/17
18:29
12/17/17
18:29
Periodicals
BHP, Esso to separately market Gippsland Basin gas, Reuters says »

The Australian…

BHP

BHP Billiton

$43.08

0.74 (1.75%)

XOM

Exxon Mobil

$83.03

0.13 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDRBF

Bombardier

17:48
12/17/17
12/17
17:48
12/17/17
17:48
Hot Stocks
Bombardier wins contract to provide Melbourne high-capacity signaling system »

Bombardier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$90.25

0.6 (0.67%)

, CMCSA

Comcast

$39.71

0.59 (1.51%)

17:38
12/17/17
12/17
17:38
12/17/17
17:38
Hot Stocks
Box Office Battle: 'Star Wars: The Last Jedi'' opens to $220M in U.S. »

Disney (DIS) and…

TWX

Time Warner

$90.25

0.6 (0.67%)

CMCSA

Comcast

$39.71

0.59 (1.51%)

CMCSK

Comcast

SNE

Sony

$44.84

0.39 (0.88%)

FOX

21st Century Fox

FOXA

21st Century Fox

$34.99

0.11 (0.32%)

LGF.A

Lionsgate

$32.99

0.49 (1.51%)

DIS

Disney

$111.27

0.7 (0.63%)

VIAB

Viacom

$30.24

0.53 (1.78%)

VIA

Viacom

$34.40

0.25 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 08

    Feb

EQIX

Equinix

$457.85

-2.5 (-0.54%)

17:17
12/17/17
12/17
17:17
12/17/17
17:17
Hot Stocks
Equinix announces acquisition of Metronode »

Equinix announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MET

MetLife

$51.41

-1.08 (-2.06%)

17:11
12/17/17
12/17
17:11
12/17/17
17:11
Periodicals
Metlife failed to pay some pensions, Reuters reports »

Metlife failed to pay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

GM

General Motors

$40.95

0.14 (0.34%)

17:06
12/17/17
12/17
17:06
12/17/17
17:06
Periodicals
GM facing $1B reckoning in ignition-switch settlement, WSJ reports »

General Motors faces a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 16

    Jan

TCEHY

Tencent

$50.31

-0.231 (-0.46%)

, BABA

Alibaba

$173.55

1.8 (1.05%)

16:58
12/17/17
12/17
16:58
12/17/17
16:58
Periodicals
Tencent to buy stake in supermarket chain, Bloomberg reports »

Tencent (TCEHY) to buy a…

TCEHY

Tencent

$50.31

-0.231 (-0.46%)

BABA

Alibaba

$173.55

1.8 (1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,179.14

4.88 (0.42%)

16:50
12/17/17
12/17
16:50
12/17/17
16:50
Periodicals
Amazon in talks to acquire Sqrrl, Axios reports »

Amazon is said to be in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

HUM

Humana

$253.64

3.03 (1.21%)

, KND

Kindred Healthcare

$8.60

0.45 (5.52%)

16:48
12/17/17
12/17
16:48
12/17/17
16:48
Periodicals
Humana in talks to acquire Kindred Healthcare, Reuters reports »

Humana (HUM) is in…

HUM

Humana

$253.64

3.03 (1.21%)

KND

Kindred Healthcare

$8.60

0.45 (5.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$48.30

-1.89 (-3.77%)

16:39
12/17/17
12/17
16:39
12/17/17
16:39
Hot Stocks
Oracle buys Aconex for $1.2B »

Oracle announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$52.93

-4.38 (-7.64%)

16:35
12/17/17
12/17
16:35
12/17/17
16:35
Hot Stocks
CSX announces death of CEO E. Hunter Harrison »

CSX issued the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$19.71

0.03 (0.15%)

16:09
12/17/17
12/17
16:09
12/17/17
16:09
Hot Stocks
Valeant, subsidiary announce early tender results »

Valeant Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Dec

  • 18

    Jun

KMF

Kayne Anderson Midstream/Energy Fund

$13.78

0.09 (0.66%)

16:01
12/17/17
12/17
16:01
12/17/17
16:01
Hot Stocks
Kayne Anderson Midstream/Energy Fund announces distribution of 30c per share »

Kayne Anderson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KYN

Kayne Anderson MLP

15:59
12/17/17
12/17
15:59
12/17/17
15:59
Hot Stocks
Kayne Anderson MLP announces distribution of 45c per share for Q4 »

Kayne Anderson MLP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KED

Kayne Anderson Energy

$16.68

-0.01 (-0.06%)

15:56
12/17/17
12/17
15:56
12/17/17
15:56
Hot Stocks
Kayne Anderson Energy announces distribution 40c per share for Q4 »

Kayne Anderson Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KYE

Kayne Anderson Energy

$10.19

-0.01 (-0.10%)

15:53
12/17/17
12/17
15:53
12/17/17
15:53
Hot Stocks
Kayne Anderson Energy announces distribution of 25c per share for Q4 »

Kayne Anderson Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$52.93

-4.38 (-7.64%)

15:18
12/16/17
12/16
15:18
12/16/17
15:18
Hot Stocks
CSX announces death of CEO E. Hunter Harrison »

CSX issued the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBOE

CBOE Holdings

$126.37

0.31 (0.25%)

11:22
12/16/17
12/16
11:22
12/16/17
11:22
Periodicals
CBOE should not be treated as 'set and forget,' Barron's says »

Bitcoin futures have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$111.27

0.7 (0.63%)

, FOXA

21st Century Fox

$34.99

0.11 (0.32%)

11:17
12/16/17
12/16
11:17
12/16/17
11:17
Periodicals
Disney/Fox 'a murky web of deals within deals,' Barron's says »

Walt Disney's (DIS)…

DIS

Disney

$111.27

0.7 (0.63%)

FOXA

21st Century Fox

$34.99

0.11 (0.32%)

FOX

21st Century Fox

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALK

Alaska Air

$70.83

1.44 (2.08%)

10:53
12/16/17
12/16
10:53
12/16/17
10:53
Periodicals
Alaska air should bounce back in 2018, Barron's says »

While shares of Alaska…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCE

Spark Therapeutics

$46.37

1.16 (2.57%)

10:42
12/16/17
12/16
10:42
12/16/17
10:42
Periodicals
Spark Therapeutics selloff may be overdone, Barron's says »

Spark Therapeutics shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jan

AAPL

Apple

$173.97

1.75 (1.02%)

10:29
12/16/17
12/16
10:29
12/16/17
10:29
Periodicals
New Apple iPhone features also bring software bugs, Barron's says »

While each new Apple…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$190.12

0.56 (0.30%)

, DIS

Disney

$111.27

0.7 (0.63%)

10:19
12/16/17
12/16
10:19
12/16/17
10:19
Periodicals
More consolidation to come after Disney/Fox deal, Barron's says »

Netflix (NFLX) success…

NFLX

Netflix

$190.12

0.56 (0.30%)

DIS

Disney

$111.27

0.7 (0.63%)

FOXA

21st Century Fox

$34.99

0.11 (0.32%)

FOX

21st Century Fox

MSGN

MSG Networks

$19.80

0.05 (0.25%)

AMCX

AMC Networks

$55.33

1.16 (2.14%)

VIAB

Viacom

$30.24

0.53 (1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

XOM

Exxon Mobil

$83.03

0.13 (0.16%)

09:22
12/16/17
12/16
09:22
12/16/17
09:22
Periodicals
Exxon disclosure of climate-change regulation impact has risks, Barron's says »

In a filing with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$111.27

0.7 (0.63%)

, FOXA

21st Century Fox

$34.99

0.11 (0.32%)

07:58
12/16/17
12/16
07:58
12/16/17
07:58
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

DIS

Disney

$111.27

0.7 (0.63%)

FOXA

21st Century Fox

$34.99

0.11 (0.32%)

FOX

21st Century Fox

T

AT&T

$38.24

0.5 (1.32%)

CHTR

Charter

$322.31

-6.37 (-1.94%)

CMCSA

Comcast

$39.71

0.59 (1.51%)

CMCSK

Comcast

VZ

Verizon

$52.67

0.33 (0.63%)

NFLX

Netflix

$190.12

0.56 (0.30%)

AMZN

Amazon.com

$1,179.14

4.88 (0.42%)

FB

Facebook

$180.18

1.79 (1.00%)

TWTR

Twitter

$22.23

-0.35 (-1.55%)

GOOG

Alphabet

$1,064.19

15.04 (1.43%)

GOOGL

Alphabet Class A

$1,072.00

14.53 (1.37%)

DFS

Discover

$74.59

0.92 (1.25%)

SYF

Synchrony

$37.19

0.2 (0.54%)

COF

Capital One

$96.31

2.25 (2.39%)

OMF

OneMain Holdings

$25.50

0.25 (0.99%)

CIT

CIT Group

$49.78

0.64 (1.30%)

SC

Santander Consumer

$17.99

-0.29 (-1.59%)

SLM

Sallie Mae

$11.17

0.18 (1.64%)

AL

Air Lease

$45.80

1.07 (2.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jan

  • 23

    Jan

  • 07

    Feb

  • 18

    Mar

  • 14

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.